177 related articles for article (PubMed ID: 34555849)
1. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia.
Tiong IS; Dillon R; Ivey A; Kuzich JA; Thiagarajah N; Sharplin KM; Kok CH; Tedjaseputra A; Rowland JP; Grove CS; Abro E; Shortt J; Hiwase DK; Bajel A; Potter NE; Smith ML; Hemmaway CJ; Thomas A; Gilkes AF; Russell NH; Wei AH
Blood Adv; 2021 Dec; 5(23):5107-5111. PubMed ID: 34555849
[TBL] [Abstract][Full Text] [Related]
2. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.
Kapp-Schwoerer S; Weber D; Corbacioglu A; Gaidzik VI; Paschka P; Krönke J; Theis F; Rücker FG; Teleanu MV; Panina E; Jahn N; Herzig J; Kubanek L; Schrade A; Göhring G; Fiedler W; Kindler T; Schroeder T; Mayer KT; Lübbert M; Wattad M; Götze KS; Horst HA; Koller E; Wulf G; Schleicher J; Bentz M; Krauter J; Bullinger L; Krzykalla J; Benner A; Schlenk RF; Thol F; Heuser M; Ganser A; Döhner H; Döhner K
Blood; 2020 Dec; 136(26):3041-3050. PubMed ID: 33367545
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Döhner H; Wei AH; Roboz GJ; Montesinos P; Thol FR; Ravandi F; Dombret H; Porkka K; Sandhu I; Skikne B; See WL; Ugidos M; Risueño A; Chan ET; Thakurta A; Beach CL; Lopes de Menezes D
Blood; 2022 Oct; 140(15):1674-1685. PubMed ID: 35960871
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients].
Zhao T; Zhu HH; Wang J; Jia JS; Yang SM; Jiang H; Lu J; Chen H; Xu LP; Zhang XH; Jiang B; Ruan GR; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):10-16. PubMed ID: 28219218
[No Abstract] [Full Text] [Related]
6. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
Bataller A; Oñate G; Diaz-Beyá M; Guijarro F; Garrido A; Vives S; Tormo M; Arnan M; Salamero O; Sampol A; Coll R; Vall-Llovera F; Oliver-Caldés A; López-Guerra M; Pratcorona M; Zamora L; Villamon E; Roué G; Blanco A; Nomdedeu JF; Colomer D; Brunet S; Sierra J; Esteve J;
Br J Haematol; 2020 Oct; 191(1):52-61. PubMed ID: 32510599
[TBL] [Abstract][Full Text] [Related]
8. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
Balsat M; Renneville A; Thomas X; de Botton S; Caillot D; Marceau A; Lemasle E; Marolleau JP; Nibourel O; Berthon C; Raffoux E; Pigneux A; Rodriguez C; Vey N; Cayuela JM; Hayette S; Braun T; Coudé MM; Terre C; Celli-Lebras K; Dombret H; Preudhomme C; Boissel N
J Clin Oncol; 2017 Jan; 35(2):185-193. PubMed ID: 28056203
[TBL] [Abstract][Full Text] [Related]
9. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
Freeman SD; Hills RK; Virgo P; Khan N; Couzens S; Dillon R; Gilkes A; Upton L; Nielsen OJ; Cavenagh JD; Jones G; Khwaja A; Cahalin P; Thomas I; Grimwade D; Burnett AK; Russell NH
J Clin Oncol; 2018 May; 36(15):1486-1497. PubMed ID: 29601212
[TBL] [Abstract][Full Text] [Related]
10. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.
Lambert J; Lambert J; Nibourel O; Pautas C; Hayette S; Cayuela JM; Terré C; Rousselot P; Dombret H; Chevret S; Preudhomme C; Castaigne S; Renneville A
Oncotarget; 2014 Aug; 5(15):6280-8. PubMed ID: 25026287
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of
Grob T; Sanders MA; Vonk CM; Kavelaars FG; Rijken M; Hanekamp DW; Gradowska PL; Cloos J; Fløisand Y; van Marwijk Kooy M; Manz MG; Ossenkoppele GJ; Tick LW; Havelange V; Löwenberg B; Jongen-Lavrencic M; Valk PJM
J Clin Oncol; 2023 Feb; 41(4):756-765. PubMed ID: 36315929
[TBL] [Abstract][Full Text] [Related]
12. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
13. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1.
Oñate G; Bataller A; Garrido A; Hoyos M; Arnan M; Vives S; Coll R; Tormo M; Sampol A; Escoda L; Salamero O; Garcia A; Bargay J; Aljarilla A; Nomdedeu JF; Esteve J; Sierra J; Pratcorona M
Blood Adv; 2022 Feb; 6(3):882-890. PubMed ID: 34516636
[TBL] [Abstract][Full Text] [Related]
15. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
Tiong IS; Dillon R; Ivey A; Teh TC; Nguyen P; Cummings N; Taussig DC; Latif AL; Potter NE; Runglall M; Russell NH; Raj K; Schwarer AP; Fong CY; Grigg AP; Wei AH
Br J Haematol; 2021 Mar; 192(6):1026-1030. PubMed ID: 32458446
[TBL] [Abstract][Full Text] [Related]
17. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.
Shayegi N; Kramer M; Bornhäuser M; Schaich M; Schetelig J; Platzbecker U; Röllig C; Heiderich C; Landt O; Ehninger G; Thiede C;
Blood; 2013 Jul; 122(1):83-92. PubMed ID: 23656730
[TBL] [Abstract][Full Text] [Related]
18. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.
Dillon LW; Gui G; Page KM; Ravindra N; Wong ZC; Andrew G; Mukherjee D; Zeger SL; El Chaer F; Spellman S; Howard A; Chen K; Auletta J; Devine SM; Jimenez Jimenez AM; De Lima MJG; Litzow MR; Kebriaei P; Saber W; Weisdorf DJ; Hourigan CS
JAMA; 2023 Mar; 329(9):745-755. PubMed ID: 36881031
[TBL] [Abstract][Full Text] [Related]
19. Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy.
Sperr WR; Zach O; Pöll I; Herndlhofer S; Knoebl P; Weltermann A; Streubel B; Jaeger U; Kundi M; Valent P
Am J Hematol; 2016 Dec; 91(12):1239-1245. PubMed ID: 27643573
[TBL] [Abstract][Full Text] [Related]
20. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.
Pratcorona M; Brunet S; Nomdedéu J; Ribera JM; Tormo M; Duarte R; Escoda L; Guàrdia R; Queipo de Llano MP; Salamero O; Bargay J; Pedro C; Martí JM; Torrebadell M; Díaz-Beyá M; Camós M; Colomer D; Hoyos M; Sierra J; Esteve J;
Blood; 2013 Apr; 121(14):2734-8. PubMed ID: 23377436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
